Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Summary Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouraci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2013-12, Vol.14 (13), p.1278-1286
Hauptverfasser: Yamada, Yasuhide, Dr, Takahari, Daisuke, MD, Matsumoto, Hiroshi, MD, Baba, Hideo, Prof, Nakamura, Masato, MD, Yoshida, Kazuhiro, Prof, Yoshida, Motoki, MD, Iwamoto, Shigeyoshi, MD, Shimada, Ken, MD, Komatsu, Yoshito, MD, Sasaki, Yasutsuna, Prof, Satoh, Taroh, MD, Takahashi, Keiichi, MD, Mishima, Hideyuki, Prof, Muro, Kei, MD, Watanabe, Masahiko, Prof, Sakata, Yuh, MD, Morita, Satoshi, Prof, Shimada, Yasuhiro, MD, Sugihara, Kenichi, Prof
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!